Veracyte, Inc. (VCYT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Veracyte’s revenue went from $65M in fiscal 2016 to $517M in fiscal 2025, growth of about 25.9% a year.
Net income in fiscal 2025 was $66M, a net margin of 12.8%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $582M and net income $127M.
Free cash flow was $127M in fiscal 2025 and positive in 3 of the 10 years shown.
The diluted share count rose 179% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $582M | $517M | $446M | $361M | $297M | $220M | $117M | $120M | $92M | $72M | $65M |
| Gross profit | $419M | $363M | $298M | $230M | $176M | — | — | $84M | $59M | $44M | $40M |
| Operating income | $99M | $58M | $16M | -$86M | -$41M | -$82M | -$35M | -$15M | -$22M | -$27M | -$29M |
| Net income | $127M | $66M | $24M | -$74M | -$37M | -$76M | -$35M | -$13M | -$23M | -$31M | -$31M |
| EPS (diluted) | $1.54 | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 | $-0.66 | $-0.27 | $-0.62 | $-0.91 | $-1.09 |
| R&D | $110M | $71M | $69M | $57M | $41M | $30M | $17M | $15M | $15M | $14M | $15M |
| Revenue growth | — | +16.0% | +23.5% | +21.8% | +35.1% | +86.9% | −2.4% | +30.8% | +27.9% | +10.5% | +31.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $174M | $136M | $75M | $44M | $8M | -$32M | -$10M | -$3M | -$14M | -$24M | -$28M |
| Capital spending | -$12M | -$10M | -$11M | -$10M | -$9M | -$5M | -$3M | -$3M | -$2M | -$2M | -$4M |
| Free cash flow | $162M | $127M | $64M | $34M | -$1M | -$37M | -$13M | -$6M | -$15M | -$26M | -$32M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $52M | $44M | $36M | $33M | $27M | $23M | $13M | $10M | $6M | $7M | $6M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $363M | $239M | $216M | $154M | $173M | $349M | $159M | $78M | $34M | $59M |
| Debt | — | $40M | $51M | $13M | $15M | $19M | $12M | $14M | $25M | $25M | $25M |
| Equity | — | $1.3B | $1.2B | $1.0B | $1.1B | $1.1B | $421M | $239M | $80M | $37M | $60M |
| Total assets | — | $1.4B | $1.3B | $1.1B | $1.2B | $1.2B | $457M | $275M | $121M | $79M | $101M |
| Shares (diluted) | 83M | 81M | 78M | 73M | 72M | 68M | 53M | 46M | 37M | 34M | 29M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 72.0% | 70.1% | 66.9% | 63.6% | 59.2% | — | — | 70.0% | 64.0% | 60.8% | 60.9% |
| Operating margin | 17.1% | 11.2% | 3.6% | -23.8% | -13.9% | -37.3% | -30.1% | -12.6% | -24.2% | -36.9% | -44.2% |
| Net margin | 21.8% | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% | -10.5% | -25.0% | -43.1% | -48.2% |
| FCF margin | 27.8% | 24.5% | 14.3% | 9.5% | -0.3% | -16.9% | -10.7% | -5.0% | -16.7% | -35.7% | -49.5% |
| ROIC | — | 4.2% | 1.2% | -7.9% | -3.0% | -6.8% | -8.2% | -6.0% | -21.2% | -42.7% | -34.1% |
| ROE | — | 5.1% | 2.1% | -7.1% | -3.4% | -6.9% | -8.3% | -5.3% | -28.8% | -83.3% | -52.6% |
Frequently asked questions
What is Veracyte’s annual revenue?
$517M in fiscal 2025 and $582M over the twelve months to September 30, 2026.
How much profit does Veracyte make?
Net income was $66M in fiscal 2025 (net margin 12.8%).
Is Veracyte’s revenue growing?
Yes: revenue rose 16.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.